What are the effects of Tirzepatide treatment on body weight and tumor growth in obese and lean Lkb1 fl/fl p53 fl/fl mice?

Tirzepatide treatment for four weeks significantly reduced tumor weight by 66.4% in HFD-fed (obese) mice and 60.1% in LFD-fed (lean) mice, demonstrating its effectiveness in inhibiting tumor growth in both groups. After two weeks of treatment, both obese and lean mice experienced significant body weight loss, with a 20.1% reduction in obese mice and a 16.8% reduction in lean mice by the end of the study. These changes occurred without noticeable adverse effects. Additionally, the expression of Ki67 (cell proliferation marker), Bcl-xL (apoptosis marker), and phosphorylated S6 (PI3K/mTOR/Akt pathway target) in tumors was significantly reduced in tirzepatide-treated groups in both obese and lean mice, with no notable distinction between the two groups.

Tirzepatide significantly inhibited both body weight and tumor growth in obese and lean Lkb1 fl/fl p53 fl/fl mice. Specifically, after four weeks of treatment, tumor weight was reduced by 66.4% in obese mice and 60.1% in lean mice. Body weight reductions of 20.1% in obese mice and 16.8% in lean mice were observed after two weeks of treatment, with no adverse effects. Furthermore, tirzepatide treatment led to a significant decrease in the expression of Ki67, Bcl-xL, and phosphorylated S6 in the tumors of both obese and lean mice.